Market Summary
USD364.42+4.05
Market Closed1.12%
BIO Alerts
BIO Stock Price
BIO RSI Chart
BIO Valuation
BIO Price/Sales (Trailing)
BIO Profitability
BIO Fundamentals
BIO Revenue
BIO Earnings
Price Action
52 Week Range
344.63509.62
(Low)(High)
Last 7 days
-1.1%
Last 30 days
-4.1%
Last 90 days
-0.1%
Trailing 12 Months
-16.7%
BIO Financial Health
BIO Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Which funds bought or sold BIO recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-12 | Farther Finance Advisors, LLC | added | 42.25 | 4,281 | 38,291 | 0.01% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | unchanged | - | -1,199 | 4,549 | -% |
2023-08-24 | Alberta Investment Management Corp | unchanged | - | -59,940 | 227,472 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | sold off | -100 | -5,200,720 | - | -% |
2023-08-21 | BOKF, NA | reduced | -27.27 | -2,236 | 3,033 | -% |
2023-08-21 | VisionPoint Advisory Group, LLC | new | - | 379 | 379 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | reduced | -0.49 | -3,116,000 | 11,550,000 | 0.11% |
2023-08-21 | OSAIC HOLDINGS, INC. | unchanged | - | -4,900 | 18,803 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -0.2 | -1,597,040 | 6,187,280 | 0.01% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -3.47 | -4,045,210 | 13,095,600 | 0.02% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
BIO Alerts
Schedule 13G FIlings of Bio Rad Laboratories
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 9.66% | 2,391,436 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 01, 2023 | blackrock inc. | 6.4% | 1,582,313 | SC 13G/A | |
| Apr 11, 2022 | schwartz alice n | 89.7% | 4,555,452 | SC 13D/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 9.21% | 2,287,465 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 7.1% | 1,768,081 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 9.18% | 2,272,373 | SC 13G/A | |
| Feb 08, 2021 | fmr llc | - | 0 | SC 13G | |
| Jan 29, 2021 | blackrock inc. | 7.6% | 1,892,336 | SC 13G/A |
Recent SEC filings of Bio Rad Laboratories
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 14, 2023 | 3 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading | |
| Sep 06, 2023 | 4 | Insider Trading |
Peers (Alternatives to Bio Rad Laboratories)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
A | 33.0B | 7.0B | -5.38% | -12.23% | 29.09 | 4.71 | 5.03% | -14.68% |
MTD | 24.7B | 4.0B | -3.30% | -3.12% | 27.83 | 6.25 | 2.30% | 16.37% |
ILMN | 21.9B | 4.5B | -17.36% | -28.94% | -5.22 | 4.9 | -4.92% | -21931.58% |
WAT | 16.2B | 3.0B | 2.60% | -2.79% | 23.99 | 5.41 | 3.16% | -3.93% |
PKI | 16.1B | 2.8B | -15.95% | -22.45% | 19.74 | 5.69 | -24.31% | 21.35% |
| MID-CAP | ||||||||
| SMALL-CAP | ||||||||
PACB | 2.4B | 146.1M | -8.89% | 61.75% | -7.4 | 16.16 | 4.72% | -55.19% |
QTRX | 960.9M | 112.0M | 5.18% | 169.83% | -14.6 | 8.58 | 0.83% | 16.42% |
ADPT | 749.3M | 189.6M | -19.57% | -31.57% | -3.92 | 3.95 | 18.74% | 17.75% |
HBIO | 175.0M | 114.1M | -1.44% | 44.37% | -32.24 | 1.53 | -5.49% | -48.58% |
CDXS | 118.7M | 99.2M | -1.73% | -74.89% | -2.09 | 1.2 | -26.56% | -199.52% |
BNGO | 99.7M | 31.5M | -1.32% | 40.85% | -0.68 | 3.16 | 35.12% | -38.47% |
NSTG | 73.7M | 143.9M | -41.73% | -89.43% | -0.44 | 0.51 | 0.71% | -18.99% |
CSBR | 72.1M | 52.7M | -20.39% | -41.08% | -9.55 | 1.37 | 2.10% | -1984.29% |
PSNL | 64.0M | 67.1M | -25.42% | -59.63% | -0.58 | 0.95 | -12.13% | -17.68% |
Bio Rad Laboratories News
Returns for BIO
Cumulative Returns on BIO
12.2%
10-Year Cumulative Returns
12.4%
7-Year Cumulative Returns
4.1%
5-Year Cumulative Returns
-10.8%
3-Year Cumulative Returns
Risks for BIO
What is the probability of a big loss on BIO?
68.8%
Probability that Bio Rad Laboratories stock will be more than 20% underwater in next one year
43.9%
Probability that Bio Rad Laboratories stock will be more than 30% underwater in next one year.
16.1%
Probability that Bio Rad Laboratories stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does BIO drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Bio Rad Laboratories was unfortunately bought at previous high price.
Drawdowns
Financials for Bio Rad Laboratories
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -0.4% | 2,769 | 2,779 | 2,802 | 2,805 | 2,871 | 2,896 | 2,923 | 2,980 | 2,880 | 2,701 | 2,546 | 2,380 | 2,294 | 2,329 | 2,312 | 2,304 | 2,289 | 2,292 | 2,289 | 2,294 | 2,283 |
| Gross Profit | -2.1% | 1,495 | 1,527 | 1,567 | 1,570 | 1,634 | 1,640 | 1,638 | 1,698 | 1,629 | 1,521 | 1,438 | 1,308 | 1,248 | 1,263 | 1,257 | 1,259 | 1,239 | 1,233 | 1,223 | 1,236 | 1,248 |
| S&GA Expenses | 0.0% | 855 | 855 | 828 | 837 | 842 | 848 | 877 | 873 | 855 | 831 | 799 | 795 | 799 | 811 | 825 | 824 | 824 | 833 | 835 | 823 | 820 |
| R&D Expenses | 0.3% | 267 | 267 | 257 | 253 | 247 | 246 | 261 | 259 | 254 | 242 | 218 | 218 | 206 | 204 | 203 | 199 | 200 | 197 | 199 | 222 | 235 |
| EBITDA | 100.0% | - | -202 | -4,666 | -7,803 | -2,594 | -224 | 5,440 | 8,561 | 5,228 | 5,464 | 5,071 | 4,693 | 2,673 | 2,197 | 2,426 | 685 | 1,371 | 942 | 678 | 1,755 | 1,444 |
| EBITDA Margin | 100.0% | - | -0.07* | -1.67* | -2.78* | - | -0.08* | 1.86* | 2.87* | 1.82* | 2.02* | 1.99* | 1.97* | 1.17* | 0.94* | 1.05* | 0.30* | 0.60* | 0.41* | 0.30* | 0.77* | 0.63* |
| Interest Expenses | 3.5% | 48.00 | 46.00 | 38.00 | 27.00 | 16.00 | 5.00 | 2.00 | 6.00 | 11.00 | 17.00 | 22.00 | 23.00 | 23.00 | 23.00 | 23.00 | 23.00 | 24.00 | 24.00 | 24.00 | 24.00 | 23.00 |
| Earnings Before Taxes | -114.0% | -526 | -245 | -4,704 | -7,824 | -2,593 | -216 | 5,449 | 8,565 | 5,227 | 5,317 | 4,918 | 4,529 | 2,509 | 2,033 | 2,261 | 520 | 1,206 | 776 | 513 | 1,600 | 1,280 |
| EBT Margin | 100.0% | - | -0.09* | -1.68* | -2.79* | - | -0.08* | 1.86* | 2.87* | 1.81* | 1.96* | 1.93* | 1.90* | 1.09* | 0.87* | 0.98* | 0.23* | 0.53* | 0.34* | 0.22* | 0.69* | 0.56* |
| Net Income | -124.0% | -428 | -191 | -3,627 | -6,027 | -1,935 | -93.15 | 4,254 | 6,666 | 4,051 | 4,100 | 3,806 | 3,521 | 1,947 | 1,579 | 1,759 | 377 | 905 | 574 | 366 | 1,277 | 1,030 |
| Net Income Margin | 100.0% | - | -0.07* | -1.29* | -2.15* | - | -0.03* | 1.45* | 2.23* | 1.40* | 1.52* | 1.50* | 1.48* | 0.85* | 0.68* | 0.76* | 0.16* | 0.40* | 0.25* | 0.16* | 0.56* | 0.45* |
| Free Cashflow | -100.0% | - | 127 | 82.00 | 152 | 364 | 459 | 536 | 667 | 586 | 529 | 476 | 369 | 322 | 381 | 359 | 272 | 244 | 162 | 156 | 148 | 116 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -12.4% | 11,978 | 13,667 | 13,502 | 12,058 | 12,682 | 14,374 | 17,799 | 19,953 | 15,118 | 13,933 | 12,973 | 12,021 | 10,097 | 8,684 | 8,009 | 7,177 | 7,647 | 6,863 | 5,611 | 6,719 | 6,386 |
| Current Assets | -4.2% | 3,139 | 3,277 | 3,158 | 3,140 | 3,250 | 3,303 | 1,990 | 2,466 | 2,289 | 2,175 | 2,140 | 2,324 | 2,133 | 2,083 | 2,180 | 2,048 | 2,088 | 2,032 | 2,023 | 2,034 | 1,992 |
| Cash Equivalents | -16.0% | 390 | 464 | 434 | 518 | 597 | 802 | 471 | 860 | 733 | 673 | 662 | 840 | 608 | 604 | 663 | 561 | 581 | 456 | 434 | 435 | 403 |
| Inventory | 3.1% | 777 | 753 | 719 | 686 | 657 | 605 | 572 | 589 | 599 | 605 | 622 | 640 | 628 | 557 | 554 | 588 | 590 | 590 | 584 | 601 | 591 |
| Net PPE | - | - | - | 499 | - | - | - | 512 | - | - | - | 491 | - | - | 486 | 499 | 496 | 499 | 503 | 509 | 484 | 490 |
| Goodwill | 0.9% | 412 | 408 | 406 | 400 | 347 | 346 | 347 | 292 | 292 | 292 | 292 | 292 | 292 | 264 | 264 | 264 | 235 | 231 | 220 | 502 | 500 |
| Liabilities | -9.5% | 3,531 | 3,904 | 3,886 | 3,605 | 3,760 | 4,191 | 4,114 | 4,621 | 3,523 | 3,324 | 3,093 | 3,196 | 2,744 | 2,391 | 2,254 | 2,046 | 2,160 | 1,999 | 1,591 | 1,818 | 1,747 |
| Current Liabilities | -1.3% | 582 | 590 | 569 | 571 | 614 | 648 | 681 | 650 | 587 | 610 | 632 | 987 | 927 | 869 | 905 | 434 | 446 | 444 | 451 | 453 | 442 |
| Long Term Debt | - | - | - | 1,198 | - | - | - | 11.00 | - | - | - | 12.00 | - | - | - | 14.00 | - | - | - | 439 | 439 | 439 |
| LT Debt, Non Current | 0.0% | 1,198 | 1,198 | 1,198 | 1,197 | 1,197 | 1,197 | 11.00 | 11.00 | 11.00 | 11.00 | 12.00 | 12.00 | 12.00 | 12.00 | 14.00 | 438 | 438 | 438 | 439 | - | - |
| Shareholder's Equity | -13.5% | 8,447 | 9,764 | 9,615 | 8,454 | 8,945 | 10,203 | 13,685 | 15,332 | 11,595 | 10,609 | 9,890 | 8,825 | 7,353 | 6,293 | 5,757 | 5,131 | 5,487 | 4,864 | 4,020 | 4,900 | 4,639 |
| Retained Earnings | -11.7% | 8,805 | 9,967 | 9,898 | 9,047 | 9,210 | 10,138 | 13,525 | 15,081 | 11,159 | 10,245 | 9,268 | 8,429 | 7,123 | 6,157 | 5,471 | 4,917 | 5,185 | 4,586 | 3,722 | 4,551 | 4,281 |
| Additional Paid-In Capital | 2.3% | 474 | 463 | 447 | 431 | 472 | 459 | 442 | 421 | 460 | 445 | 429 | 412 | 429 | 424 | 410 | 396 | 411 | 403 | 394 | 382 | 377 |
| Accumulated Depreciation | - | - | - | 1,009 | - | - | - | 1,002 | - | - | - | 961 | - | - | 876 | 883 | 851 | 850 | 828 | 818 | 812 | 799 |
| Shares Outstanding | -0.8% | 29.00 | 30.00 | - | 30.00 | 30.00 | 30.00 | - | 30.00 | 30.00 | 30.00 | - | 30.00 | 30.00 | 30.00 | - | 30.00 | 30.00 | 30.00 | - | 30.00 | 30.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 18.5% | 287 | 242 | 194 | 275 | 505 | 606 | 669 | 793 | 698 | 636 | 585 | 450 | 414 | 478 | 458 | 403 | 366 | 288 | 286 | 250 | 216 |
| Share Based Compensation | - | - | - | - | - | - | - | - | - | - | - | - | 43.00 | 36.00 | - | - | 36.00 | 33.00 | - | - | - | - |
| Cashflow From Investing | 47.7% | -189 | -361 | -1,207 | -1,705 | -1,709 | -1,665 | -797 | -289 | -117 | -105 | -69.89 | -71.34 | -272 | -198 | -208 | -202 | -122 | -190 | -186 | -145 | -130 |
| Cashflow From Financing | -38.3% | -293 | -212 | 974 | 1,065 | 1,058 | 1,182 | -55.43 | -481 | -465 | -471 | -523 | -105 | -110 | -123 | -22.76 | -64.98 | -62.66 | -49.03 | -48.68 | 2.00 | 1.00 |
| Buy Backs | - | 181 | - | 216 | 125 | 125 | - | 50.00 | 50.00 | 50.00 | 50.00 | 100 | 108 | 113 | 128 | 28.00 | 69.00 | 64.00 | 49.00 | 49.00 | - | 2.00 |
BIO Income Statement
2023-06-30Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Net sales | $ 681,110 | $ 691,099 | $ 1,357,954 | $ 1,391,161 |
| Cost of goods sold | 318,627 | 296,068 | 633,054 | 593,495 |
| Gross profit | 362,483 | 395,031 | 724,900 | 797,666 |
| Selling, general and administrative expense | 207,824 | 207,793 | 433,377 | 404,485 |
| Research and Development Expense | 65,042 | 64,346 | 139,993 | 123,881 |
| Segment profit (loss) | 89,617 | 122,892 | 151,530 | 269,300 |
| Interest expense | 12,343 | 10,720 | 24,680 | 14,768 |
| Foreign exchange (gains) losses, net | (1,253) | 897 | (3,600) | (1,231) |
| Marketable Securities, Unrealized (Gain) Loss | 1,595,442 | 1,338,190 | 1,612,967 | 5,883,307 |
| Other Nonoperating Income (Expense) | 16,488 | 6,710 | 66,919 | 39,307 |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | (1,500,427) | (1,220,205) | (1,415,598) | (5,588,237) |
| (Provision) benefit for income taxes | 338,176 | 295,091 | 322,309 | 1,295,776 |
| Net income attributable to Bio-Rad | $ (1,162,251) | $ (925,114) | $ (1,093,289) | $ (4,292,461) |
| Basic earnings per share: | ||||
| Net income per share basic attributable to Bio-Rad | $ (39.59) | $ (31.05) | $ (37.09) | $ (143.74) |
| Weighted average common shares - basic | 29,355 | 29,794 | 29,475 | 29,863 |
| Diluted earnings per share: | ||||
| Weighted average common shares - diluted | 29,355 | 29,794 | 29,475 | 29,863 |
BIO Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| ASSETS: | ||
| Cash and cash equivalents | $ 390,001 | $ 434,215 |
| Short-term investments | 1,332,685 | 1,356,457 |
| Restricted investments | 5,560 | 5,560 |
| Accounts receivable, net | 491,575 | 494,645 |
| Inventory | 776,600 | 719,316 |
| Prepaid expenses | 122,641 | 124,179 |
| Other current assets | 19,804 | 23,604 |
| Total current assets | 3,138,866 | 3,157,976 |
| Property, plant, and equipment | 1,575,075 | 1,508,020 |
| Less: accumulated depreciation and amortization | 1,061,062 | 1,009,408 |
| Property, plant and equipment, net | 514,013 | 498,612 |
| Operating lease right-of-use assets | 173,922 | 180,952 |
| Goodwill, net | 411,519 | 406,488 |
| Purchased intangibles, net | 328,710 | 332,147 |
| Other investments | 7,311,135 | 8,830,892 |
| Other assets | 100,064 | 94,599 |
| Assets | 11,978,229 | 13,501,666 |
| LIABILITIES AND STOCKHOLDERS' EQUITY: | ||
| Accounts payable | 149,535 | 135,041 |
| Accrued payroll and employee benefits | 154,704 | 194,790 |
| Current maturities of long-term debt and notes payable | 476 | 465 |
| Income and other taxes payable | 74,481 | 32,428 |
| Current operating lease liabilities | 36,543 | 36,336 |
| Other current liabilities | 166,243 | 169,648 |
| Total current liabilities | 581,982 | 568,708 |
| Long-term debt, net of current maturities | 1,198,384 | 1,197,716 |
| Deferred income taxes | 1,401,827 | 1,770,481 |
| Operating lease liabilities | 146,849 | 153,597 |
| Other long-term liabilities | 202,294 | 195,912 |
| Total liabilities | 3,531,336 | 3,886,414 |
| Stockholders' equity: | ||
| Additional paid-in capital | 473,872 | 447,454 |
| Retained earnings | 8,804,664 | 9,898,203 |
| Accumulated other comprehensive loss | (372,862) | (466,822) |
| Total stockholders' equity | 8,446,893 | 9,615,252 |
| Total liabilities and stockholders' equity | 11,978,229 | 13,501,666 |
| Common Class A [Member] | ||
| Stockholders' equity: | ||
| Common stock | 2 | 2 |
| Common Class B [Member] | ||
| Stockholders' equity: | ||
| Common stock | 1 | 1 |
| Treasury Class A [Member] | ||
| Stockholders' equity: | ||
| Treasury stock | $ (458,784) | $ (263,586) |
| Treasury Stock, Common | ||
| Stockholders' equity: | ||
| Treasury Stock, Shares | 1,160,074 | 640,492 |
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.